Roche inaugurates Translational and Clinical Research Center at the Alexandria Center for Life Science in New York City
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alexandria Real Estate Equities, Inc. (NYSE: ARE) inaugurated the Translational and Clinical Research Center (TCRC) at the prestigious Alexandria Center for Life Science in Manhattan's East Side Medical Corridor by hosting New York officials and dignitaries as well as life science leaders from institutions across the U.S.
Bayer accelerates clinical development of promising new drug candidates
- Details
- Category: Bayer
Following the recent commercial introduction of five new drugs to address the medical needs of patients with various diseases, Bayer is now accelerating the development of further five promising drug candidates which are currently undergoing phase I and II clinical studies. The company plans to progress these five new highly innovative drug candidates in the areas of oncology, cardiology, and women's health into phase III clinical studies by 2015.
Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin
- Details
- Category: Boehringer Ingelheim
Anticoagulants are an indispensable treatment to prevent dangerous blood clots that can cause devastating ischaemic strokes in patients with atrial fibrillation or life-threatening pulmonary embolism in patients with venous thromboembolism.(1,2) An increased risk of bleeding is a known possible complication of all anticoagulant therapies.(3)
Secukinumab (AIN457) showed superiority over Enbrel®
- Details
- Category: Novartis
Novartis announced results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis[1]. Enbrel is a current standard-of-care anti-TNF medication approved to treat moderate-to-severe plaque psoriasis.
International Atherosclerosis Society and Pfizer Independent Grants for Learning & Change collaborate on new grant opportunity
- Details
- Category: Pfizer
The International Atherosclerosis Society (IAS) and Pfizer Independent Grants for Learning & Change (IGLC) have announced their collaboration on a new grant opportunity focused on improving care for patients around the world with medium or high levels of cardiovascular risk, with a particular focus on dyslipidemia.
Amgen successfully completes Onyx Pharmaceuticals tender offer
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) for $125 per share in cash. As announced on Aug. 25, the purchase price is $9.7 billion net of estimated Onyx cash.
Takeda and Lundbeck announce FDA approval of Brintellix™ (vortioxetine)
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Company Limited (Takeda) jointly announced that the U.S. Food and Drug Administration (FDA) has approved Brintellix™ (vortioxetine) for the treatment of adults with major depressive disorder (MDD), a debilitating mental health illness affecting approximately 14 million adult Americans in a given year[1].
More Pharma News ...
- Olivier Brandicourt appointed as new CEO of Bayer HealthCare
- Nintedanib* extended survival beyond one year for advanced adenocarcinoma patients after prior first-line chemotherapy
- Cimzia® (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
- Bayer's investigational drug Riociguat granted FDA orphan drug designation
- Amgen and ShanghaiTech University announce plans for Amgen China R&D center
- Malaria No More and Novartis launch Power of One, a global digital fundraising campaign to help eliminate malaria deaths
- GSK signs a multi-year agreement with BARDA to supply the US government with anthrax treatment